AUC-guided vancomycin dosing did not significantly reduce the incidence of acute kidney injury compared to trough-only dosing (7.65% vs 6.06%; P=0.56).
Cohort (n=348)
No
Does AUC-guided vancomycin dosing reduce acute kidney injury and improve clinical outcomes compared to trough-only dosing in patients with S. aureus infections?
AUC-guided vancomycin dosing did not significantly reduce the incidence of acute kidney injury or improve clinical outcomes compared to trough-only dosing, although it did reduce the total daily dose.
Absolute Event Rate: 7.65% vs 6.06%
p-value: p=0.56
Background The 2020 consensus guidelines for drug monitoring of vancomycin recommended AUC-guided dosing to reduce acute kidney injury (AKI) and improve clinical outcomes in patients with serious methicillin-resistant Staphylococcus aureus (MRSA) infections previously managed with trough concentrations of 15–20 mg/L. Objectives To determine if AUC-guided dosing of vancomycin reduces AKI and improves clinical outcomes including non-invasive infections with S. aureus compared with trough-only dosing broadened to concentrations of 10–20 mg/L. Methods A retrospective, single-center, cohort study was conducted over 12 months comparing Bayesian software-guided AUC-dosing with trough-only dosing. Information collected included patient demographics, co-morbidities, concurrent nephrotoxins, assessment measures of drug exposure, and patient outcomes. Nominal data were analyzed using the chi-square test, and continuous data using the independent t test. Results Based on the Kidney Disease Improving Global Outcomes (KDIGO) criteria, the incidence of AKI was 7.65% and 6.06% ( P = 0.56), among 183 patients in the AUC-guided and 165 subjects in the trough-only groups, respectively. Individuals in the trough-only group were younger, had fewer co-morbidities and admissions to the ICU. A lower incidence of AKI findings among trough-only subjects was likely a result of the duration of therapy (mean of 4.2 days), mean trough concentrations <15 mg/L, and fewer concurrent nephrotoxins. AUC-guided dosing significantly reduced the total daily dose, 2.29 vs 2.54 g/day ( P = 0.01), but provided no significant reductions in cumulative dose, duration of therapy, length of hospital stays, or overall patient outcomes. Conclusion AUC-guided vancomycin dosing did not reduce the incidence of AKI nor impact patient outcomes vs trough-only dosing. Successful clinical outcomes with lower average trough concentrations may have resulted from the treatment of nonbacteremic skin soft tissue infections (SSTI), suggesting an indication for further exploration of vancomycin dosing strategies.
Barrons et al. (Tue,) conducted a cohort in S. aureus infections (n=348). AUC-guided vancomycin dosing vs. Trough-only dosing (10-20 mg/L) was evaluated on Acute kidney injury (AKI) (p=0.56). AUC-guided vancomycin dosing did not significantly reduce the incidence of acute kidney injury compared to trough-only dosing (7.65% vs 6.06%; P=0.56).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: